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In IgA nephropathy (IgAN), pathogenic IgA1 is likely derived
from bone marrow (BM) cells and exhibits reduced
O-galactosylation. Defective O-galactosylation may arise from
the compromised expression or function of the enzyme
b-galactosyltransferase and/or its molecular chaperone
(Cosmc). We measured B-cell O-galactosylation activity and
the relative gene expression of b-galactosyltransferase and
Cosmc in peripheral blood and BM taken from patients with
IgAN and controls. O-galactosylation activity was measured
in peripheral and BM B cells by the incorporation of
radiolabeled galactose into an asialo-mucin acceptor. Gene
expression of b-galactosyltransferase and Cosmc was
measured by real-time PCR and related to that of the enzyme
GalNAc-T2 (UDP-N-acetyl-a-D-galactosamine:polypeptide
N-acetylgalactosaminyltransferase-2), which synthesizes the
core O-glycan. Neither the B-cell O-galactosylation activity
nor the gene expression of the enzyme or chaperone was
different between patients and controls. However, the
relationships between the O-glycosylation of serum IgA1,
galactosylation activity, and b-galactosyltransferase gene
expression showed different patterns in IgAN and controls. In
IgAN, O-galactosylation activity correlated with
b-galactosyltransferase gene expression, but not with IgA1
O-glycosylation, suggesting that factors other than the
availability of b-galactosyltransferase or Cosmc are
responsible for altered IgA1 O-glycosylation.
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IgA nephropathy (IgAN) is characterized by the deposition of
IgA in the glomerular mesangium, and is among the most
common forms of glomerulonephritis in developed coun-
tries.1 Although the mechanism of mesangial IgA deposition
in IgAN is not well understood, it is likely that physico-
chemical properties of the molecule are involved. Of the two
human IgA subclasses IgA1 and IgA2, IgA1 has been most
implicated in the pathogenesis of IgAN. IgA1 has a heavily O-
glycosylated hinge region between the CH1 and CH2
domains, which is absent from IgA2 and all other serum
immunoglobulins except IgD.2 Indeed, only a few serum
proteins carry O-linked glycans and IgA1 is the most
abundant of these.
The IgA1 O-glycans are of the Core-1 type, short and
simple sugar chains based on N-acetyl galactosamine
(GalNAc) O-linked to serine or threonine residues. This
can occur alone, but is usually extended with the addition of
galactose (Gal) and sialic acid (N-acetylneuraminic acid,
NeuNAc), giving rise to different O-glycan chain variants
(I–V, Figure 1a). The O-glycan chains are formed in the
Golgi apparatus during the synthesis of IgA1 by the
sequential action of glycosyltransferases (Figure 1b). Initial
linking of GalNAc to the protein backbone is catalyzed by
one of the UDP-N-acetyl-a-D-galactosamine:polypeptide
N-acetylgalactosaminyltransferase family, known as GalNAc-T2.3
Galactosylation is then effected by a core-1 b1-3 galactosyl-
transferase, C1Gal-T1.4 C1Gal-T1 activity requires the
co-expression of the chaperone protein Core-1-b3-Gal-T-
specific molecular chaperone (Cosmc),5 the availability of
which may be a limiting factor in galactosyltransferase
function.
Much research interest has been devoted to the
O-glycosylation of IgA1 in IgAN, and it is now well
established that abnormalities exist,6–9 which are of potential
pathogenic significance,10–16 and may have diagnostic value.17
The exact structural details of the IgA1 O-glycosylation
abnormality found in IgAN has proved difficult to char-
acterize, although most studies conclude that reduced
galactosylation of some of the moieties is most likely.9,10,17,18
This leads to the hypothesis that reduced activity of the
galactosylating enzyme C1Gal-T1 may be responsible, due to
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either some defect in the enzyme or its expression, or
secondary to the reduced availability of the chaperone
protein Cosmc. In the hematological disorder Tn syndrome
and in some cancers, a total lack of C1Gal-T1 activity in the
affected clones results in undergalactosylation of the core-1
O-glycans of membrane proteins resulting in the abnormal
surface expression of the Tn antigen (GalNAc),19 an
analogous situation to IgA1 in IgAN. In a Tn-expressing T-
cell line (Jurkat), the lack of C1Gal-T1 activity is due to a
mutation in the Cosmc gene rather than in C1Gal-T1 itself.5
Some support exists for both these possibilities in peripheral
blood (PB) B cells in IgAN: we previously published a study
showing indirect evidence of reduced O-galactosylation
activity,20 and a more recent report demonstrated reduced
Cosmc gene expression.21 Any defect is unlikely to affect all
O-glycosylated proteins in IgAN, as we have shown that C1
inhibitor, another serum protein carrying O-glycans, is
normal in IgAN,7 as is the O-glycosylation of IgD.22
Therefore, changes in C1Gal-T1 or Cosmc activity are likely
to be restricted to IgA1-producing B cells only.
Circulating B lymphocytes are mostly naive or memory
cells, and are not in the process of producing the secreted
IgA1 molecules found in the serum and deposited in the
kidney. Although the majority of IgA production normally
occurs at mucosal sites, this does not appear to be the source
of abnormal IgA1 production in IgAN. Mesangial IgA1 in
IgAN is polymeric: this type of IgA1 production is reduced in
mucosal tissue in the patients,23,24 but increased in the bone
marrow (BM)25,26 and tonsil,27 and these latter sites are
therefore the most likely origin of pathogenic IgA1 molecules.
Therefore, the aim of this study was to look for defects of
O-galactosylation factors that may account for abnormal
IgA1 O-glycosylation in IgAN, focusing on the BM. We
directly measured B-cell O-galactosylation activity effected by
the galactosylating enzyme C1Gal-T1 with its molecular
chaperone Cosmc. We also measured BM C1Gal-T1 and
Cosmc mRNA expression in relation to that of GalNAc-T2.
RESULTS
Lectin binding of plasma IgA1
As is generally found in IgAN, serum IgA1 from patients had
significantly higher Helix aspersa (HA) lectin binding than
did control IgA1 (mean A492HA/A492IgA1±s.e.m.: IgAN
1.838±0.0397, control 1.562±0.0473, P¼ 0.014).
Purity and yield of B-cell preparations
Representative PB and BM preparations were 89 and 70%
positive for the B-cell surface marker CD22, and negative for
T cell and monocyte markers (CD3, CD14). The lower
percentage of B cells in BM is probably due to the earlier
expression of CD19 (used for selection) than CD22 (used for
detection) by B cell precursors: CD22-negative cells had the
morphological appearance of immature lymphocytes. PB and
BM B-cell lysates with total protein concentrations of more
than 100 mg were obtained from all subjects.
C1Gal-T1/Cosmc O-galactosylation activity in PB and BM B
cells
The O-galactosylation activity of PB and BM B cells in each
subject is shown in Table 1. We found no significant
difference between patients with IgAN and controls in the
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Figure 1 | O-glycosylation of human IgA1. (a) The hinge region of
human IgA1 carries a series of approximately five Core-1 type
carbohydrates per heavy chain. The diagram illustrates the various
possible structures of these carbohydrate moeities. All the variations
are based on N-acetyl galactosamine (GalNAc, open squares) O-linked
to serine or threonine residues (I). GalNAc can be extended with the
addition of galactose (Gal, open circles) in b1,3 linkage to form the
basic Core-1 structure (II), which may be sialyated with the addition
of one (III and IV) or two (V) N-acetylneuraminic acid units (NeuNAc,
shaded diamonds). As the hinge regions of different IgA1 molecules
can potentially carry a varied number and mixture of the different
chain configurations, a wide array of O-glycoforms is theoretically
possible. (b) O-glycosylation of IgA1 is catalyzed by the sequential
action of highly specific glycosyltransferases. GalNAc is first added to
serine or threonine by UDP-N-acetyl-a-D-galactosamine:polypeptide
N-acetylgalactosaminyltransferase-2 (GalNAc-T2). The moiety is
galactosylated in the b1,3 configuration by Core-1 b1-3
galactosyltransferase-1 (C1Gal-T1), which requires the presence of the
Core-1-b3-Gal-T-specific molecular chaperone (Cosmc).
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C1Gal-T1/Cosmc activity of either PB or BM B cells. Nor was
there any significant difference in activity between PB and
BM B cells in either the IgAN or the control groups.
However, in IgAN, there was a significant positive correlation
between the O-galactosylation activity of PB and BM B cells
(Figure 2); this relationship was not seen in the controls
(r¼ 0.139, P¼ 0.650, data not shown).
Correlation of B-cell enzyme activity and lectin binding of
IgA1
In IgAN, HA lectin binding of serum IgA1 showed a
significant positive correlation with O-galactosylation activity
in BM B cells, but not with PB B cells (Figure 3a and b). By
contrast, in controls, there was a significant inverse correla-
tion between lectin binding of serum IgA1 and O-
galactosylation activity of both PB and BM B cells (Figure
3c and d).
Real-time PCR
Table 2 shows the gene expression ratios in patients with
IgAN and controls. There was no difference between the
subject groups in the ratios of C1Gal-T1:GalNAc-T2 or
C1Gal-T1:Cosmc in PB or BM lysates.
Correlation of enzyme gene expression with lectin binding of
plasma IgA1 and C1Gal-T1 activity
There was no correlation between the lectin binding of
plasma IgA1 and the PB or BM gene expression ratios of
C1Gal-T1:GalNAc-T2 or C1Gal-T1:Cosmc in either the IgAN
or control groups (data not shown).
In the IgAN group only, B-cell C1Gal-T1/Cosmc activity
showed negative correlations with both C1Gal-T1:Cosmc Ct
(threshold cycle) and C1Gal-T1:GalNAc-T2 ratios in PB and
BM samples (Figure 4), although most of these did not reach
statistical significance. As Ct is inversely proportional to gene
expression, these correlations indicate a positive relationship
between expression of C1Gal-T1 and O-galactosylation in
these samples. No such correlation was found in the ratio of
Cosmc:GalNAcT-2 (PB r¼ 0.336, P¼ 0.342; BM r¼0.364,
P¼ 0.24), suggesting that the C1Gal-T1 gene expression is
responsible for this relationship. There was no indication of
any correlation of gene expression ratios and O-galactosyla-
tion activity in the controls (data not shown).
DISCUSSION
The O-glycosylation of IgA1 has received much attention in
IgAN since the original reports of altered lectin binding to
serum IgA1. It is apparent that there is over-representation of
IgA1 molecules with certain O-glycan patterns in the serum
of patients with IgAN and that these O-glycoforms
predominate in the mesangial deposits.14,28 The detailed
structure of these abnormal IgA1 O-glycoforms has yet to be
fully elucidated, but most of the available evidence suggests
under-galactosylation, leading to increased exposure of the
inner core GalNac moieties and the underlying protein
backbone, and to reduced sialylation (Figure 1). It has been
suggested that reduced O-galactosylation may result from
reduced activity of C1Gal-T1, the intracellular enzyme that
catalyzes the addition of galactose to O-linked GalNAc
moieties.20,29,30 We previously reported evidence that the
activity of this enzyme may indeed be reduced in PB B cells in
IgAN.20 However, the assay used in that study measured
enzyme activity only indirectly by monitoring changes in
lectin binding of an acceptor prepared by degalactosylation of
Table 1 | B-cell O-galactosylation activity (AU lg1 total cell
protein)
Subject no.
IgAN Control
PB BM PB BM
1 1.18 1.33 1.57 1.46
2 0.80 0.88 1.35 0.82
3 1.25 1.28 1.30 1.50
4 1.11 1.50 3.78 2.34
5 1.22 1.02 1.26 0.73
6 1.15 0.50 1.40 1.62
7 1.16 0.77 1.18 0.87
8 1.44 1.27 1.65 1.60
9 0.92 1.04 1.15 0.58
10 1.38 2.70 1.10 0.85
11 1.45 2.90 0.80 0.73
12 1.24 2.19 0.74 4.40
13 1.40 1.70
Mean (s.e.m.) 1.19 (0.06) 1.45 (0.22) 1.44 (0.21) 1.48 (0.29)
P-value paired t-test;
PB vs BM
0.205 0.905
P-value unpaired t-test;
IgAN vs control
0.275 0.937
AU, arbitrary units; BM, bone marrow; IgAN, IgA nephropathy; PB, peripheral
blood.
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Figure 2 | O-galactosylation activity in B cells from peripheral
blood and bone marrow in patients with IgAN. The C1Gal-T1/
Cosmc activity of lysates of purified B cells was measured in an
assay based on incorporation of radiolabeled UDP-Gal into an
ovine submaxillary mucin acceptor. The results were expressed as
arbitrary units per microgram total lysate protein (AU mg1).
In IgAN (closed circles), there was a significant positive
correlation between the C1Gal-T1/Cosmc activity of B cells from
peripheral blood and bone marrow. No such relationship was seen
in controls.
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pooled IgA1 after incubation with cell lysates. The theoretical
strength of this earlier assay lies in its use of IgA1 as the
acceptor, which is clearly more relevant for our purpose than
ovine submaxillary mucin (OSM). However, the changes in
lectin binding could have been due to factors other than
C1Gal-T1-mediated regalactosylation of the O-glycan moi-
eties, and the results are therefore less specific and reliable
than the direct measurement of galactose incorporation into
the mucin acceptor preparation used here, which has
previously been validated for the measurement of C1Gal-
T1.31 As the functions of C1Gal-T1 and Cosmc are intimately
related, any assay of C1Gal-T1 in cell lysates, including that
used here, will also include the activity of Cosmc. Differences
in O-galactosylation activity between different lysates may
reflect alterations in the function of either or both of these
proteins. It is neither possible nor physiologically relevant to
separate them.
In this study, in addition to PB B cells, we studied
O-galactosylation activity in B cells from BM, the likely site of
abnormal IgA1 production in IgAN. We also used real-time
PCR to investigate gene expression of GalNAc-T2 and C1Gal-
T1, the two major enzymes involved in synthesis of these
O-glycan chains, and Cosmc, the essential chaperone protein
of C1Gal-T1.
Compared to the controls, the serum IgA1 of the cohort of
IgAN patients studied displayed abnormally high HA lectin
binding. HA lectin recognizes GalNAc and its binding is high
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Figure 3 | Serum IgA1 O-glycosylation and B-cell O-galactosylation activity in IgAN and controls. The O-glycosylation pattern of serum
IgA1 was shown by its binding of the lectin from Helix aspersa (HA), which recognizes ungalactosylated O-linked GalNAc, in an ELISA-type
system. The higher the HA binding, the lower the overall galactosylation of the IgA1 sample. In IgAN (closed circles, a and b), the HA lectin
binding of serum IgA1 showed no relationship with the C1Gal-T1/Cosmc O-galactosylation activity of peripheral blood (PB) B cells (a), but a
significant positive correlation with that of bone marrow (BM) B cells (b). By contrast, in controls (closed diamonds, c and d), HA lectin binding
of serum IgA1 had a significant inverse correlation with the C1Gal-T1/Cosmc activity of both PB (c) and BM (d) B cells.
Table 2 | Gene expression ratios
IgAN Control
PB BM PB BM
C1Gal-T1:GalNAc-T2 ratio
Mean (s.e.m.) 1.17 (0.07) 0.94 (0.03) 1.12 (0.02) 0.95 (0.03)
P-value IgAN vs control 0.504 0.756
C1Gal-T1:Cosmc
Mean (s.e.m.) 1.19 (0.07) 0.93 (0.01) 1.24 (0.03) 0.95 (0.03)
P-value IgAN vs control 0.600 0.426
BM, bone marrow; C1Gal-T1, Core-1 b1-3 galactosyltransferase-1; Cosmc, Core-1-b3-
Gal-T-specific molecular chaperone; IgAN, IgA nephropathy; PB, peripheral blood.
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when IgA1 is undergalactosylated,32 leading to increased
exposure of terminal GalNAc moieties. This observation
confirmed that these patients displayed the usual
O-glycosylation defect seen in IgAN and were a representative
group of subjects for this work. The relationship between
IgA1 lectin binding and C1Gal-T1/Cosmc O-galactosylation
activity differed in patients and controls, as is logical if
abnormal IgA1 O-galactosylation in IgAN arises from
alterations in intracellular processing. In the controls, lectin
binding showed a significant inverse correlation with enzyme
activity in both PB and BM B cells. This is as expected, as the
higher the O-galactosylation activity, the more galactosylated
the O-glycans of IgA1 will be, and therefore the fewer
ungalactosylated moieties will be available for HA binding.
This correlation supports the validity of the assays used in
this study for both the enzyme activity and lectin binding.
However, this inverse relationship was not seen in IgAN.
There was no correlation between HA lectin binding to
serum IgA1 and PB B-cell O-galactosylation activity in the
patients, but there was a positive correlation with BM B-cell
activity. This suggests that in the BM, some factors other than
the availability or activity of C1Gal-T1 and/or Cosmc
underlie reduced O-galactosylation of IgA1.
In the controls, there was no correlation between the
O-galactosylation activity of PB and BM B cells, suggesting
that the two populations are distinct from one another in this
respect. However, in IgAN, there was a significant positive
correlation between B cells from these two sources, indicating
a link, such as a common origin or involvement in the same
type of immune activity. This is interesting in light of other
studies from our group, which suggest that the ‘abnormal’
O-glycosylation pattern of IgA1 in IgAN actually represents a
normal O-glycoform that is usually found in mucosal but not
in systemic IgA1.33 In controls, the majority of circulating
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Figure 4 | B-cell O-galactosylation activity and galactosyltransferase gene expression ratios in IgAN. The mRNA expression of GalNAc-T2,
C1Gal-T1, and Cosmc in peripheral blood (PB) and bone marrow (BM) lysates was measured by real-time PCR. The results were expressed as
ratios of the threshold cycle (Ct) values obtained for each gene, as the two enzymes and Cosmc are functionally related and balanced
availability of each is required for the assembly of fully galactosylated Core-1 O-glycans. In IgAN (closed circles), a negative relationship was
observed between the ratios of C1Gal-T1:Cosmc (a and b) and C1Gal-T1:GalNAc (c and d) and B-cell O-galactosylation activity in both PB and
BM. As Ct is inversely proportional to gene expression, this indicates a positive relationship between C1Gal-T1 gene expression and O-
galactosylation activity. Although most of these correlations did not reach statistical significance, their consistent pattern implies a biologically
significant association. No such relationship between gene expression ratios and O-galactosylation activity was observed in the controls.
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IgA1 B cells are trafficking to the mucosa, whereas those
resident in the BM are systemic: these are different
populations. In IgAN, the BM contains increased numbers
of plasma cells producing IgA1 that contains J chain and is
therefore polymeric,23 another mucosal feature. The relation-
ship between circulating and BM B cells observed here may
be a further indicator of the abnormal presence of mucosal-
type B cells in the BM in IgAN.
We found no difference between IgAN and controls in the
O-galactosylation activity of either PB or BM B cells in this
study. In agreement with the above discussion, this suggests
that some factors other than absolute levels of C1Gal-T1/
Cosmc activity are responsible for abnormally low
O-galactosylation of IgA1 in patients with IgAN. This finding
conflicts with our previously published results,20 which did
suggest that O-galactosylation activity was reduced in PB B
cells in IgAN. This reason for this discrepancy is not clear, but
may be a consequence of the more accurate assay system used
here.
To assess mRNA expression, we used ratios of the different
genes to one another. Absolute gene expression levels are
irrelevant as they vary with cell number, type, and activity in
each sample, and there is no suitable housekeeping gene for
such experiments. However, the three genes examined here
are functionally related to one another, as they are involved in
the sequential construction of the Core-1 O-glycan chains.
For a given degree of galactosylation, the ratios C1Gal-
T1:GalNAc-T2 and C1Gal-T1:Cosmc should remain con-
stant. Low expression of C1Gal-T1 in relation to that of
GalNAc-T2 would be expected to result in reduced
galactosylation of the O-glycans. The same effect would
occur with relative underexpression of Cosmc as compared to
C1Gal-T1, as this chaperone protein is essential for the
activity of C1Gal-T1. Therefore, if reduced availability of
either C1Gal-T1 or Cosmc is responsible for the under-
galactosylation of IgA1 in IgAN, we would expect to find this
reflected in the gene expression ratios. However, we found no
difference between IgAN and controls in the relative
expression of C1Gal-T1 and either GalNAc-T2 or Cosmc in
PB or BM, arguing against a fundamental imbalance in the
expression of the genes encoding these O-galactosylating
proteins in the patients.
In IgAN PB cells, there was a significant negative
correlation between the ratio C1Gal-T1:Cosmc and B-cell
O-galactosylation activity (Figure 4a). As Ct is inversely
proportional to gene expression, this indicates that low
enzyme activity may be associated with low C1Gal-T1 gene
expression in relation to Cosmc; that is, either C1Gal-T1 is
low or Cosmc is high. The same relationship was seen in the
BM in IgAN, although this correlation did not reach
statistical significance (Figure 4b). In both PB and BM, the
ratio C1Gal-T1:GalNAc-T2 also showed a non-significant
trend toward a negative correlation with C1Gal-T1 activity
(Figure 4c and d), suggesting that C1Gal-T1 expression is low
in relation to GalNAc-T2. Although these correlations were
not statistically significant, their consistent pattern suggests
that they may indicate a biologically significant imbalance in
C1Gal-T1 expression compared to the other two genes. As
the ratio of Cosmc:GalNAcT-2 did not correlate with the
C1Gal-T1 expression at all, relatively low C1Gal-T1 expres-
sion rather than raised Cosmc or GalNAc-T2 expression is
most likely to underlie the above correlations.
The results of this study show no absolute deficiency in
B-cell C1Gal-T1/Cosmc-catalyzed O-galactosylation activity
or the expression of O-galactosylating enzymes in IgAN that
might account for abnormal IgA1 O-galactosylation. How-
ever, we did find a number of subtle imbalances in the
pattern of C1Gal-T1/Cosmc activity and expression in the
patients. The O-galactosylation activity in control B cells
showed a positive correlation with the degree of
O-galactosylation (inverse to HA lectin binding), as would
be expected. However, the opposite was found in BM B cells
in IgAN, suggesting that some factors other than C1Gal-T1
activity dictate the degree of IgA1 O-galactosylation in IgAN.
Although the availability of Cosmc is a possible limiting
factor, this did not appear to be the case in our study: the
O-galactosylation activity correlated with the C1Gal-T1 gene
expression rather than with that of Cosmc. Overall, our
results suggest that abnormal O-glycosylation in IgAN is not
due to an O-galactosyltransferase or Cosmc deficiency or
defect, although we cannot exclude the possibility that a
minor subpopulation of B cells, not detected in these
experiments, is abnormal in this regard. This hypothesis is
consistent with our previous reports in which we found that
in both IgAN and controls, the pattern of O-glycosylation
varies at different stages of B-cell maturation,22 and also in
different immune responses,33 indicating that the O-glyco-
sylation profile of IgA1 is influenced by control mechanisms
related to the immunological situation in which it is
produced. Patients are able to produce IgA1 with a range
of galactosylation profiles, and it seems likely that the
presence of hypogalactosylated IgA1 in the serum in IgAN is
a reflection of aberrant immune activity rather than a
fundamental defect in O-glycosylation capacity. Future work
should focus on the factors controlling the profile of IgA1
O-glycosylation in different immunological situations.
MATERIALS AND METHODS
Materials
Unless otherwise stated, all consumables were from Sigma Chemical
Co. (Poole, UK).
Subjects and samples
Twelve patients with IgAN (10 males, median age 39 years, range
29–69 years; details shown in Table 3) and 13 matched controls
undergoing elective orthopedic surgery (7 males, median age 37
years, range 17–75 years) were recruited. All patients had biopsy-
proven IgAN with microscopic hematuria and/or proteinuria less
than 1.4 g per 24 h. At the time of the study, no subject had an
intercurrent illness, and none of the IgAN patients had macroscopic
hematuria. The median serum creatinine in the IgAN patients was
105 mmol l1 (range 58–162), and the median time from renal
biopsy was 3 years (range 0.5–8). No subject was receiving
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immunosuppressive treatments at the time of the study or in the
previous 24 months. BM aspirates from the posterior iliac crest and
60 ml venous blood were collected at the same time. The study was
approved by the LNR Research Ethics Committee, and all subjects
gave written informed consent.
IgA1 lectin binding
The binding of the O-glycan-specific lectin Helix aspersa (HA) to
plasma IgA1 was measured by modified enzyme-linked immuno-
sorbent assay, exactly as described previously.22 All samples were run
in a single assay to allow direct comparison.
Preparation of B-cell lysates for C1Gal-T1 assay
Plasma was separated from the blood samples and stored at 80 1C
until required, and the remaining PB cells resuspended in Hank’s
balanced salt solution (HBSS). BM aspirates were diluted with an
equal volume of HBSS and vortexed to break up cell clumps.
Mononuclear cells were isolated from PB and BM by density
gradient centrifugation over Ficoll 400 (density 1.077), washed in
HBSS, and resuspended in culture medium (RPMI 1640 containing
10% heat-inactivated fetal calf serum, 2 mM L-glutamine,
100 IU ml1 penicillin, and 100 mg ml1 streptomycin). The cells
were then kept overnight at 37 1C in a sterile 5% CO2 humid
atmosphere.
B lymphocytes were separated from the BM and PB mono-
nuclear cell samples by positive selection on CD19 magnetic beads
(Dynabeads; Invitrogen, Paisley, UK) following the manufacturer’s
instructions. Purity of the recovered cell populations was assessed by
morphological examination and immunohistochemical staining for
surface markers. Finally, the B cells were lysed in 2% Triton X-100 in
Tris-buffered saline.
Two different human monocyte cell lines, THP-1 (ECACC no:
88081201) and U937 (ATCC CRL 1593), were used as a standard and
an internal control in the C1Gal-T1 assay. These were maintained in
standard culture conditions in culture medium as above, feeding and
passaging as necessary for consistent, healthy cell growth. When
required for the assay, the cells were washed in protein-free HBSS
and lysed in 2% Triton X-100/Tris-buffered saline.
The total protein concentration of the B-cell lysates was
measured using a commercial kit (DC Protein Assay; Bio-Rad,
Hemel Hempstead, UK) according to the manufacturer’s instruc-
tions.
Preparation of asialo-OSM acceptor for C1Gal-T1/Cosmc
assay
Sialyl-OSM (sOSM) (derived from homogenized sheep submaxillary
salivary glands) was kindly donated by Dr Tony Corfield (University
of Bristol, UK). Desialylation was achieved by three sequential mild
acid hydrolyses in 0.1 M HCl at 80 1C, followed by neutralization
with 1 M NaOH. After dialyzing against ultrapure water, the acceptor
was lyophilized and stored at 4 1C. This acceptor preparation was
evaluated against an equivalent prepared, characterized, and
routinely used by Dr Corfield, and was shown to perform
satisfactorily in preliminary assays, the two acceptors incorporating
equivalent amounts of (14C)Gal when incubated with the same
lysate samples.
C1Gal-T1/Cosmc assay
The O-galactosylation activity measured in this assay relies on the
function of both C1Gal-T1 and its chaperone protein Cosmc. The
assay was carried out in 75 ml volumes. A volume of 50 ml of
substrate solution (50 mM Tris (pH 7.0) containing 2 mg ml1 asialyl
OSM (aOSM), 20 mM MnCl2, 1% Triton X-100, 0.25 mM UDP-Gal,
and 10 ml ml1 UDP(14C)Gal) was added to 25 ml of cell lysate in
1.5 ml polypropylene tubes and vortexed. After 1 h of incubation at
37 1C, the reaction was quenched by the addition of 500ml of
phosphotungstic acid/trichloroacetic acid (5%/15% (v/v)). After
cooling at 4 1C for 30 min, the mixture was centrifuged at 14 000 g
and the supernatant discarded. The product was washed twice in
1 ml 95% ethanol, drained, dissolved in 500 ml of 0.2 M KOH, and
transferred to scintillation vials containing 2 ml Ecoscint A
scintillation fluid (National Diagnostics, Atlanta, GA, USA). After
the chemiluminescence had faded, scintillation counting was
performed with 226Ra external standardization and quench correc-
tion. The results were expressed in disintegrations per minute
(DPM).
Each test lysate sample was run in duplicate. A standard curve of
eight serial dilutions of U937 cell lysate, and internal controls of
three dilutions of THP-1 lysate and one blank were also set up each
time the assay was performed.
The U937 lysate protein was arbitrarily assigned an enzyme
activity of 1 arbitrary unit/mg total protein (1 AUmg1), and
standard curves constructed from which the O-galactosylation
activity of both the test and the internal control lysates were read
and expressed as AUmg total lysate protein.
Table 3 | Patient details
Patient no. Sex Age Serum creatinine BP (mm Hg) BP Rx: no. of drugs ACEI or ARB Proteinuria Hematuria
Patients
1 M 50 87 No other information—notes lost
2 F 32 78 110/70 0 No 0 3+
3 M 69 153 140/75 2 No 0 0
4 M 51 96 146/100 1 No 1+ 0
5 M 63 161 170/95 4 Yes 2+ 3+
6 M 52 96 125/80 0 No 0 0
7 M 29 103 130/100 1 No 2+ 3+
8 F 39 69 138/84 0 No 1+ 3+
9 M 39 103 140/90 0 No 2+ 0
10 M 36 93 128/78 0 No 2+ 3+
11 M 40 468 156/100 1 No 2+ 3+
12 M 34 101 120/80 1 Yes 3+ 3+
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BP, blood pressure; F, female; M, male.
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O-glycosyltransferase gene expression
RNA extraction and cDNA synthesis. Total cellular RNA was
extracted from PB mononuclear cells and BM aspirates using
RNAqueous-4 PCR (Ambion, Austin, TX, USA). The optional
DNase 1 and DNase inactivation steps were included to remove any
residual genomic DNA. cDNA was synthesized from the RNA using
Reverse Transcriptase System (Promega, Southampton, UK), using
random primers.
Real-time PCR. cDNA sequences were amplified in an MX4000
thermocycler (Stratagene, Amsterdam, The Netherlands) using
primers detailed in Table 4. A volume of 50 ml amplification reaction
mixes containing 45 mM Tris-HCl (pH 8.8), 11 mM (NH4)2SO4,
4.5 mM MgCl2, 20 mM each of dATP, dCTP, dTTP, dGTP,
0.11 mg ml1 bovine serum albumin, 6.7 mM b-mercaptoethanol,
0.44mM Na2EDTA, 75 pM passive reference dye (Stratagene), SYBR
Green I (Invitrogen) diluted 1:30 000, 1 U Jumpstart Taq polymerase
and 10 pmol forward and reverse primers were used. The reactions
were run in for 1 cycle of 10 min at 95 1C and then for 40 cycles of
30 s at 95 1C, 1 min at 62 1C (1,3 C1Gal-T1) or 65 1C (GalNAc-T2
and Cosmc), and 30 s at 72 1C Each reaction was run in duplicate.
The results were obtained as Ct at which a standard fluorescence
level (set to 0.1) was reached in each reaction. The higher the
expression of each gene in the original sample, the lower the cycle
number at which this threshold is reached, or in other words, a high
gene expression gives a low Ct value and vice versa. Results were
expressed as ratios of the Ct values of the genes to one another. As
GalNAc is the core sugar to which the Gal is subsequently added, we
expressed C1Gal-T1 in terms of GalNAc-T2, that is, C1Gal-
T1:GalNAc-T2. The activity of C1Gal-T1 requires the chaperone
protein Cosmc, and therefore we calculated the ratio C1Gal-
T1:Cosmc.
Statistical analysis. Lectin binding results of serum IgA1, and
O-galactosylation activity and gene expression ratios of cell lysates
from IgAN and controls were compared by unpaired Student’s
t-tests. The O-galactosylation activity of PB and BM B cells from the
same subjects was compared by paired t-tests. Linear regression
analysis was used to investigate the relationships between B-cell O-
galactosylation activity, gene expression, and IgA1 lectin binding.
Results quoted in the text are mean values of groups, ±s.e.m.
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